The EBMT is proud to announce that its Registry has achieved a landmark milestone of 10,000 chimeric antigen receptor T-cell (CAR-T) therapy patients.

The EBMT proudly commemorates its 50th anniversary, marking five decades of transformative advancements in the field of hematopoietic cell transplantation (HCT) and cellular therapy.

An international team started the research project CERTAINTY in December 2023.

After one year and a half of work, the EBMT launches its new and improved patient Registry database, co-funded by the European Union in a grant called EuroTraCTOR.

The EBMT and EHA are proud to announce the release of the first-ever open-access book on CAR-T cells to be officially launched during the EBMT-EHA 4^th European CAR-T Cell Meeting.

The results of the EBMT phase III RACE trial was published today by the New England Journal of Medicine.

Hospital Privado Universitario de Córdoba, Argentina is first to earn Certificate of Completion for Step One under the FACT-JACIE International Standards for HCT Stepwise Accreditation Program.

The EBMT and the EHA announce a strategic partnership to empower Europe to become a global leader in the cellular therapy field for haematological diseases.

The Gemeinsame Bundesausschuss (G-BA) published its directions on the treatment of German patients with CAR T-cell therapies.

The EBMT announced the results of the phase III RACE trial during EBMTs virtual 46^th Annual Meeting.

The EBMT announces a new collaboration with Kite, a Gilead Company, to study the long-term outcomes of patients treated with Yescarta® (axicabtagene ciloleucel), a chimeric antigen receptor T cell (CAR T) therapy.